SCHEMBL4402201

SCHEMBL4402201

COC(=O)c1cc(COS(C)(=O)=O)cc(OC)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA12 O43570 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
TCF4 P15884 1/20 0.39
CTNNB1 P35222 1/20 0.39
POLB P06746 2/20 0.39
KDM4E B2RXH2 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
HPGD P15428 3/20 0.39
TP53 P04637 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
PKM P14618 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17570969 0.89 CA1 (0.48) ALDH1A1CA1CA2CA12CA7
SCHEMBL4209463 0.87 TAS2R14 (0.45) CA1CA2POLBSMN1; SMN2TP53
SCHEMBL17615247 0.85 CA1 (0.44) ALDH1A1CA1CA2CA12CA7
SCHEMBL4207152 0.83 HPGD (0.55) ALDH1A1SMN1; SMN2HPGDNPC1RAB9A
SCHEMBL31634963 0.83 ALDH1A1 (0.49) ALDH1A1CA1CA2CA12CA7
SCHEMBL22946239 0.83 ALDH1A1 (0.49) ALDH1A1CA1CA2CA12CA7
SCHEMBL23017630 0.82 NOTUM (0.47) ALDH1A1CA1CA2CA12CA7
SCHEMBL4966993 0.82 CA12 (0.42) ALDH1A1CA1CA2CA12CA7
SCHEMBL31385499 0.82 NOTUM (0.47) ALDH1A1CA1CA2CA12CA7
SCHEMBL31385471 0.82 CA12 (0.42) ALDH1A1CA1CA2CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090312321-A1 COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS IRM LLC (BM) 2009-12-17 US disclosed
US-20090312321-A1 COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS IRM LLC (BM) 2009-12-17 US disclosed
WO-2007136465-A2 COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS IRM LLC (BM) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312321-A1 COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS PTK2B, SGK2, FRK ALDH1A1 4315/4885CA1 4268/4885CA2 2414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.